japan urology association disclosure of coi presentershinji kageyama, md i declare that there are no...
Post on 05-Jan-2016
217 Views
Preview:
TRANSCRIPT
Japan Urology Association
Disclosure of COI
Presenter Shinji Kageyama, MD I declare that there are no conflicts of interest associated
with this study.
Acitive Surveillance
AS: chose progress observation approach rather than actual carcinostatic treatment
Feel uneasiness by patientsReceived many inquiries by
patients seeking for something better once PSA level increases
3
Case 61-year-old patient (presently 71 years old)
Patient’s Option: Observation of PSA levelHistory of disease:In 2004 Biopsy at one hospital in Hamamatsu City and detected PSA 5.2 and found that G3+4 was 2/6. Diagnosis – T2aNoMo. Selected “progress observation” per his request.
In 2006 re-biopsy at the same hospitalDecided for continuation of “progress observation” for G3+4 was 1/6.PSA increased to 7.2 at most; PSA stayed between 5 and 6
In April, 2013, a patient moved to Shizuoka CityContinued “progress observation” at my clinicPresent symptoms/test results: TG, LDL-C is a little higher than limits; otherwise, no mentionable symptoms
G3+4 G3+4 Began observation at my clinic
Feb-
06
May-0
6
Aug-0
6
Nov-0
6
Feb-
07
May-0
7
Aug-0
7
Nov-0
7
Feb-
08
May-0
8
Aug-0
8
Nov-0
8
Feb-
09
May-0
9
Aug-0
9
Nov-0
9
Feb-
10
May-1
0
Aug-1
0
Nov-1
0
Feb-
11
May-1
1
Aug-1
1
Nov-1
1
Feb-
12
May-1
2
Aug-1
2
Nov-1
20
1
2
3
4
5
6
7
8
9
10PSA
PSA
2/6 1/6MRI
Treatment for Minimally Invasive Cancer
Metformin Vit D Curcumin Agaricus PDT Peptide Vaccine
6
7
Gold LotionTM
Extract of Citrus produced in Japan
Unsyu Mikan (tangerin), Citrus limon, navel oranges, Citrus Hassaku, Citrus natsudaidai, Miyauchi Iyo hort, Aloe
7
8
Compounds contained in Citrus Peel Extract
• Pectin• anti-ulcer 、 disinfection 、
immune activation• Essential oil
• Terpenoids: limonene, linalool, etc.
• other volatile oil• antioxydation 、 disinfec
tion • Flavonoids
• Polyhydroxyflav(an)ones (PHFs)
• PMFs – polymethoxyflavones• anti-
immflamation 、 anti-carcinogenesis 、 antioxydation 、 anti-atherosclerosis effects
• Carotenoids• Hesperidin• Narindin
• Anti-cancer
GL の各種パラメータに対する影響
Anti-immflammation
Inhibit metastasis
Induction ofApoptosis
Inhibit proliferation
10
Inhibition of LNCaP, PC-3 cell Proliferation by Hesperidin
Effective on both androgen dependent/non-dependent
PC-3 derived xenograft model11
Professor Min-Hsiung Pan, Taiwan University, TaiwanProfessor Chi-Tang Ho, Rutgers University, USA
Food & Function, 2013, DOI: 10.1039/c3fo60037h
Results
Inhibit tumor proliferation (peritoneal application)
Inhibit tumor proliferation(oral application)
Oral application proved to be effective against androgen non-dependent cancer
Case 61-year-old patient (presently 71 years old)
Began GL oral application
Began observation at my clinic
Mar-1
3
Apr-1
3
May-1
3
Jun-
13
Jul-1
3
Aug-1
3
Sep-
13
Oct-1
3
Nov-1
3
Dec-1
3
Jan-
14
Feb-
14
Mar-1
4
Apr-1
4
May-1
4
Jun-
14
Jul-1
4
Aug-1
40
2
4
6
8
10
12
PSA
PSA
前立腺がんに対する GL 使用GL Oral Application against Prostate Cancer
14
Yearstarted
Age Years of applica-tion
Dosage( CC)
PSAStartingPSA
Least PSA level
Other combined treatment
2004 80 1yr. 10 278 1 LH-RH
2005 67 2yr. 15 24.4 13.3 LH-RH( after
application13.3⇒0.03 )
2008 66 6yr. 10 0.3 0.03 after brachy therapy
2012 70 2yr. 10 ~30
0.2 0.05 daVinc
2013 69 1.5yr. 30 16.1 10.5 with other supplement
2014 71 4mos.
15 10.1 6.9 none
Data provided by Miyauchi Citrus Research Center, Ltd.
Issues to be considered Considering this case, was Increased PSA at
the beginning of this observation at my clinic a palindromia of cancer?
Considering decreased PSA by GL application, simply treated inflammation? Recommended strongly another biopsy
Unclear most adequate dosage of GL What about testosterone level? Require longer observation
15
top related